SCHEMBL6981849

SCHEMBL6981849

Cc1ccc(S(=O)(=O)N2CCN(C(=O)C(CC(C)C)NC(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.57
MEN1 O00255 3/20 0.57
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
MDM2 Q00987 1/20 0.54
MAPK1 P28482 1/20 0.50
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
AIMP2 Q13155 1/20 0.49
HRH2 P25021 2/20 0.49
HRH1 P35367 2/20 0.49
P2RX7 Q99572 2/20 0.48
NPSR1 Q6W5P4 1/20 0.47
F13A1 P00488 2/20 0.46
TGM2 P21980 2/20 0.46
TGM1 P22735 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3115917 0.83 KMT2A (0.59) KMT2AMEN1MAPK1ALDH1A1LMNA
SCHEMBL3115927 0.83 KMT2A (0.59) KMT2AMEN1MAPK1ALDH1A1LMNA
SCHEMBL6981469 0.79 MAPK1 (0.48) KMT2AMEN1MAPK1ALDH1A1LMNA
SCHEMBL18410584 0.78 TGM2 (0.65) KMT2AMEN1NPC1RAB9AMDM2
SCHEMBL6978507 0.78 NPC1 (0.51) KMT2AMEN1NPC1RAB9AMDM2
SCHEMBL6985831 0.78 NPC1 (0.51) KMT2AMEN1NPC1RAB9AMDM2
SCHEMBL6983395 0.78 NPC1 (0.51) KMT2AMEN1NPC1RAB9AMDM2
SCHEMBL3170253 0.77 ALDH1A1 (0.54) KMT2AMEN1NPC1RAB9AALDH1A1
SCHEMBL1706174 0.77 MAPK1 (0.55) KMT2AMEN1MAPK1ALDH1A1LMNA
SCHEMBL1706172 0.77 MAPK1 (0.55) KMT2AMEN1MAPK1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
US-5935959-A CYSTEINE PROTEASE INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 1999-08-10 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed